GERO.AI utilizes Whole-Exome Sequencing data for in-human AI Drug Discovery, while GeroSense is the arm of Gero creating Digital Biomarkers. You can find more about GeroSense on the dedicated website.
About Gero
Our mission: Hacking Complex Diseases and Aging with AI for Drug Discovery and Digital Biomarkers
GERO.AI models are originating from the physics of complex dynamic systems. We have presented our unique approach in Frontiers in Genetics. We combine the potential of deep neural networks with the physical models to study dynamical processes and undersend what drives a disease.
Gero conducts high-quality research studies backed by collaboration with researchers from the leading global institutions such as the Harvard Medical School, Massachusetts Institute of Technology, University of Edinburgh, National University of Singapore, and Roswell Park Comprehensive Cancer Center to develop new therapies. The company is a regular contributor to peer-reviewed journals, including recently accepted publication in Science.
Gero is funded by AI champions, including AIMATTER founders (recently acquired by Google). In 2019, Gero was also named one of the leading companies in artificial intelligence for lifespan extension along with Google and IBM.
Gero team
Сuring the uncurable with Landau Lifshitz book and a bit of AI
Peter Fedichev
CEO. Co-founder at Gero
I am doing my best to make aging history
Maxim Kholin
Co-founder at Gero
Science is a pricey thing. On a mission to fund science against aging
Alex Kadet
Head of Business Development
Data Inquisitor
Konstantin Avchaciov
Data scientist - Life extension research
Ilya Sokolov
Data Scientist
Right-hand-woman to aging hackers
Olga Druzhinina
Deputy Finance Director
Understanding the Universe, while providing real-world solutions
Kirill Denisov
Junior Deep Learning Researcher
Ph.D., Head of Preclinical Development
Olga Burmistrova
Chairman of the Board
Yury Melnichek
Gero team
Сuring the uncurable with Landau Lifshitz book and a bit of AI
Peter Fedichev
CEO. Co-founder at Gero
I am doing my best to make aging a history
Maxim Kholin
Co-founder at Gero
Olga Burmistrova
Ph.D., Head of Preclinical Development
Science is a pricey thing. On a mission to fund science against aging
Alex Kadet
Head of Business Development
Data Inquisitor
Konstantin Avchaciov
Data scientist — Life extension research
Ilya Sokolov
Data Scientist
Right-hand-woman to aging hackers
Olga Druzhinina
Deputy Finance Director
Understanding the Universe, while providing real-world solutions
Kirill Denisov
Junior Deep Learning Researcher
Yury Melnichek
Chairman
Key collaborators
  • Robert J. Shmookler Reis, PhD
    Longevity pioneer, Professor and Udupa Chair in Geriatrics, Reynolds Institute on Aging/Dept. of Geriatrics; Professor of Biochemistry/Molecular Biology and Pharmacology/Toxicology, Univ. of Arkansas for Medical Sciences
  • Brian Kennedy, PhD
    Distinguished Professor of Biochemistry and Physiology, Yong Loo Lin School of Medicine, NUS, Singapore, Buck Institute for Research on Ageing, Novato, CA, USA.
  • Andrei Gudkov, PhD
    Senior Vice President of Research Programming and Development of Roswell Park Cancer Institute.CSO of Everon Biosciences, founded in 2010 in a partnership with Roswell Park Cancer Institute with the goal of developing anti-aging medicines.
  • Vadim Gladyshev, PhD
    Professor of Medicine, professor at Harvard Medical School & Brigham and Women's Hospital. Expert and pioneer in antioxidant/redox biology
  • Yuri Aulchenko, PhD
    CSO and Founder of PolyOmica
    Honorary Professor of the University of Edinburgh, listed among "The World's Most Influential Scientific Minds" in the category "Molecular Biology & Genetics"by Thomson-Reuters.
Careers in GERO.AI
We are a next-gen AI for Drug Discovery company making cutting-edge science and continuously looking for great people to join a fast-growing team of like-minded pioneers to solve some of the most critical problems humanity faces.
We are looking for:
We are looking for: